Evidence map›Paper›PMID 42600921›Full record

ArticleContemporary clinical trials2026

A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers.

Steven K Sutton, Kea Turner, Katherine Chung-Bridges, Susan T Vadaparampil, Rania Abdulla, Mariana Arevalo, Natasha Avrilien, Margaret M Byrne, Edelise Endemano, Jennifer Garcia Hernandez and 8 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07222995 (A Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in Federal Qualified Health Centers), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07222995 narecruitingnot on this map

A Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in Federal Qualified Health Centers

TypeinterventionalSponsorH. Lee Moffitt Cancer Center and Research InstituteRan2025 to 2030Enrolled2,900ConditionsSkin CancerArmsPrecision Prevention Booklet, Standard Prevention Booklet
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Steven K SuttonDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Steve.Sutton@moffitt.org.
Kea TurnerDivision of Health Systems, Policy, and Innovation, School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: Kea.turner@unc.edu.
Katherine Chung-BridgesHealth Choice Network, Miami, FL, USA. Electronic address: kchung@hcnetwork.org.
Susan T VadaparampilDepartment of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: susan.vadaparampil@moffitt.org.
Rania AbdullaNon-Therapeutic Research Office, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Rania.Abdulla@moffitt.org.
Mariana ArevaloDepartment of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: mariana.arevalo@moffitt.org.
Natasha AvrilienHealth Choice Network, Miami, FL, USA. Electronic address: navrilien@hcnetwork.org.
Margaret M ByrneDepartment of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: margaret.byrne@moffitt.org.
Edelise EndemanoHealth Choice Network, Miami, FL, USA. Electronic address: eendemano@hcnetwork.org.
Jennifer Garcia HernandezNon-Therapeutic Research Office, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Jennifer.garciahernandez@moffitt.org.
Jada G HamiltonDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hamiltoj@mskcc.org.
Erin LyjakNon-Therapeutic Research Office, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: erin.lyjak@moffitt.org.
Zoe ParralesNon-Therapeutic Research Office, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: zoe.parrales@moffitt.org.
Jairo RamosDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Jairo.Ramos@moffitt.org.
Maritza TorresTampa Family Health Centers, Tampa, FL, USA. Electronic address: mbtorres@tfhc.org.
Brian WhiteTampa Family Health Centers, Tampa, FL, USA. Electronic address: bwhite@tfhc.org.
Jennifer L HayDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hayj@mskcc.org.
Peter A KanetskyDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: peter.kanetsky@moffitt.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centersR01CA291735 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI JENNIFER L HAY, PETER A KANETSKY · 2024 to 2026
$3.4M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA291735
6 · The paper itself

Abstract

backgroundSkin cancers are the most common type of cancer in the United States, occur in all segments of the population, and are preventable. Our previous research with primary care patients' demonstrated interest in and efficacy of a precision prevention intervention providing feedback on MC1R risk level (higher versus average) in combination with prevention education materials relative to a standard educational intervention. Our current study is a hybrid type 1 effectiveness-implementation trial deployed at six federally-qualified health centers. This paper presents the study protocol.

methodsA community advisory panel will guide development of study materials and measures. Staff training at each clinic will be completed in-person. Patients will be approached and screened in-person. Those completing genetic testing and the baseline survey will be randomized to the precision versus standard intervention for each risk level with a target sample size of 286 for each combination. Primary outcomes of effectiveness, assessed at 6 and 12 months, include a tanning score (5 items assessing intentional and unintentional tanning), number of sunburns, conduct of a skin self-examination, and electronic health record documentation of clinician-patient communication about skin cancer prevention. Effectiveness comparisons will focus on the precision relative to the standard intervention among higher risk participants. Implementation data will be collected to identify barriers and facilitators.

resultsEffectiveness and implementation outcomes will be evaluated following study completion.

conclusionsResults will guide subsequent scale-up of the precision intervention, including modifications of the intervention as well as methods for implementation. CLINICAL TRIALS IDENTIFIER: NCT07222995.

Indexed as

Patient Education as TopicSkin NeoplasmsFeedbackFemaleGenetic TestingHumansMaleMulticenter Studies as TopicPrimary Health CareRandomized Controlled Trials as TopicResearch DesignRisk AssessmentSelf-ExaminationSunburnUnited StatesGenetic riskHybrid type 1InterventionPreventionSkin cancer

Identifiers

PMID42600921
PMCPMC13527874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.